National Cancer Institute CRADA
Executive Summary
NCI seeks pharmaceutical company partner to develop LMB-7 recombinant immunotoxin for certain cancers. In an April 14 Federal Register notice announcing the availability of the Cooperative Research and Development Agreement, NCI states that LMB-7 "has been shown to cause the complete regression of human cancers growing in immunodeficient mice." Questions concerning the LMB-7 CRADA should be directed to Ira Pastan, MD, NCI Division of Cancer Biology Diagnosis and Centers, (301) 496-4797.